Psychiatric practice in Europe is entering a period of significant regulatory change. The EU AI Act, the world's first comprehensive legal framework for artificial intelligence, is now progressively entering into force, and it treats AI tools deployed in mental health settings with particular seriousness. For psychiatrists evaluating or already using AI-assisted tools in their clinical work, understanding how this regulation classifies those tools is no longer a compliance abstraction. It has direct implications for what can be deployed, under what conditions, and with what obligations toward patients.

Why mental health AI tools face heightened regulatory scrutiny

The EU AI Act does not apply a uniform standard across all AI applications in healthcare. Its risk classification framework is sensitive to the clinical context in which a tool operates, the nature of the decisions it influences, and the characteristics of the population it affects. Mental health practice sits at the intersection of several factors that consistently attract the Act's most demanding requirements: the vulnerability of the patient population, the severity of potential harms from erroneous AI outputs, and the degree to which clinical decisions in psychiatry depend on nuanced, relationship-based judgement that is difficult to audit or reverse.

A peer-reviewed analysis published in 2024 concluded that significant risks are being taken with the use of generative AI in mental health, and that the EU AI Act, while directly applicable, may be insufficient on its own to address the specific legal and ethical gaps that arise in psychiatric contexts. That assessment underlines why psychiatrists cannot treat regulatory compliance as a vendor's problem alone.

What the EU AI Act says about high-risk AI in healthcare

The Act establishes a tiered classification system. At the top are prohibited AI practices, systems that are banned outright. Below that sits the high-risk category, which carries the most extensive compliance obligations. Article 6 of the Act defines two routes to high-risk classification: first, where an AI system is a safety component of a product already covered by EU harmonisation legislation listed in Annex I (which includes the Medical Device Regulation, or MDR); second, where the system falls within one of the categories listed in Annex III.

Annex III explicitly includes AI systems intended for diagnosing, treating, monitoring, or predicting health conditions, including mental disorders. AI tools designed to assist in psychiatric diagnosis, predict deterioration, stratify risk, or support treatment decisions fall squarely within the high-risk designation by legislative design, not by interpretation.

The distinction between a prohibited system and a high-risk one matters in practice. Prohibited systems, such as those that exploit psychological vulnerabilities to manipulate behaviour in ways that cause harm, cannot be deployed at all. A legal analysis examining prohibited practices under the Act identified mental health chatbots that use persuasive dialogue or gamification to influence patient behaviour as potentially crossing into prohibited territory, depending on their design and deployment context. High-risk systems, by contrast, can be deployed but only after satisfying a rigorous set of conformity requirements.

How vulnerability of the population shapes risk classification

One of the less-discussed dimensions of the Act's risk framework is its attention to the characteristics of affected individuals, not just the technical function of the AI system. The Act explicitly requires that the vulnerability of users and affected persons be considered in the risk assessment process. Patients receiving psychiatric care, including those with severe mental illness, those in acute crisis, and those with conditions that affect cognition or decision-making capacity, are recognised under EU law as a vulnerable group.

This has a practical consequence for classification. A documentation tool that generates structured clinical notes might perform a technically comparable function in dermatology and in psychiatry. But the clinical context in psychiatry, where notes may directly inform decisions about detention, medication, or crisis intervention, and the vulnerability of the patient population means that the same technical function carries a different regulatory weight. Psychiatrists should not assume that because a tool is marketed as a documentation assistant rather than a diagnostic aid, it is automatically subject to lighter regulatory requirements.

Which AI tools in mental health practice are most likely to be classified as high-risk

Mapping common AI tool categories against the Act's classification criteria is not straightforward, because classification depends on intended purpose and deployment context rather than product category alone. That said, several tool types used in psychiatric practice are consistently likely to attract high-risk designation:

• Risk stratification and triage tools: Systems that assess suicide risk, predict psychiatric deterioration, or prioritise patients for urgent review are among the clearest cases for high-risk classification. A systematic review published in 2026 found that suicide prevention and crisis detection was a common domain for AI mental health chatbots, precisely the context where erroneous outputs carry the most severe consequences.

• Diagnostic support tools: AI systems that suggest diagnoses, differential diagnoses, or diagnostic codes for mental health conditions fall within Annex III's explicit scope.

• Mood and symptom tracking systems: Where these systems generate outputs that directly inform clinical decisions, rather than simply recording patient-reported data, they are likely to be treated as high-risk.

• AI-enabled psychotherapy agents: Academic research on large language model (LLM)-based psychotherapy agents has highlighted the absence of standardised safety evaluation methods for this category and documented harms from unregulated AI chatbots used by vulnerable populations, reinforcing the case for high-risk classification.

• Clinical decision support tools: Any AI system that recommends or influences treatment decisions in a mental health setting, including medication suggestions or care pathway recommendations, falls within the high-risk framework.

A critical point noted in the European Commission's guidance on AI in healthcare is that providers who believe their system does not meet the high-risk threshold must document that assessment. The burden of demonstrating lower-risk classification rests with the provider, not with the regulator.

Where clinical documentation tools sit in the classification framework

Ambient documentation assistants, tools that transcribe and structure clinical encounters into notes, referral letters, or discharge summaries, occupy a more contested position in the classification framework. The question of whether such tools are automatically high-risk does not have a single answer.

A documentation tool that passively transcribes speech and presents unstructured text for a clinician to review and edit sits at a different point on the risk spectrum than one that generates structured clinical notes, applies diagnostic codes, or produces outputs that are routinely used without significant clinician modification to inform care decisions. The Act's classification logic focuses on the intended purpose and the realistic use of the system's output. As the academic analysis of the AI Act in healthcare confirms, the interaction between the AI Act and the MDR is particularly relevant here: if a documentation tool qualifies as Software as a Medical Device under the MDR, it is likely to attract high-risk classification under the AI Act as well.

In a mental health context, the threshold at which a documentation tool becomes high-risk is arguably lower than in other specialties. Clinical notes in psychiatry are frequently used to support decisions about compulsory treatment, capacity assessments, and safeguarding referrals. Where AI-generated notes directly feed into those decisions, even if the clinician nominally reviews them, the tool's output is functionally influencing a high-stakes clinical decision affecting a vulnerable individual.

One important nuance: guidance from the Medical Device Coordination Group (MDCG) clarifies that AI systems developed and used exclusively within a single healthcare institution, without being placed on the market, may be subject to modified obligations. This applies to a limited subset of in-house tools and does not affect commercially procured products.

Conformity requirements psychiatrists and practice managers must verify

For AI systems classified as high-risk, the Act imposes a set of obligations that must be satisfied before deployment. From the perspective of a psychiatrist or practice manager procuring an AI tool, the following are the key requirements to verify with any vendor:

• CE marking and MDR compliance: Where the tool qualifies as a medical device, CE marking under the MDR is required. High-risk AI tools that are also medical devices must satisfy both the MDR conformity assessment and the AI Act's requirements. These are parallel obligations, not alternatives.

• Technical documentation: Vendors must maintain comprehensive technical documentation demonstrating the system's design, development process, training data characteristics, and performance validation. This documentation should be available for inspection.

• Risk management system: A documented risk management process aligned with ISO 14971 or equivalent standards is required. The 2026 systematic review on mental health chatbots found that 78.8 per cent of reviewed studies were rated high risk for cybersecurity evaluation rigour, indicating that formal adversarial testing and structured threat modelling remain rare. Psychiatrists should probe this gap directly with vendors.

• Human oversight mechanisms: High-risk systems must be designed to allow effective human oversight, including the ability for clinicians to override, disregard, or intervene in the system's output. This is a legal requirement, not a discretionary feature.

• Logging and audit trails: The system must automatically log its operations to a degree that supports post-hoc review of how outputs were generated. This is particularly relevant in psychiatry, where clinical decisions may be subject to legal scrutiny.

• Accuracy, robustness, and cybersecurity: Vendors must demonstrate that the system performs to a defined level of accuracy and is resilient to errors and adversarial inputs.

A clinician-focused guide published in Psychiatria Danubina noted that these regulatory concepts can be obscure for clinicians, and recommended that health professionals develop sufficient familiarity with the framework to evaluate AI tools critically before adoption.

Transparency obligations when using AI in mental health consultations

The AI Act's transparency requirements are distinct from, though complementary to, the conformity obligations described above. In a clinical setting, they translate into concrete duties that fall on the deployer of the system, which in most cases means the healthcare institution or practice, not the vendor.

Where an AI system is involved in a clinical interaction, whether generating notes, supporting a diagnostic decision, or conducting any part of an assessment, patients have a right to be informed. In mental health practice, this obligation carries particular weight. The therapeutic relationship is foundational to psychiatric care, and patients' trust in that relationship depends in part on their understanding of how decisions about their care are being made.

Key transparency obligations include:

• Disclosure of AI involvement: Patients must be informed when an AI system is being used in a way that materially affects their care. This applies even when the clinician retains final decision-making authority.

• Interaction with GDPR: Mental health data is classified as a special category under the General Data Protection Regulation (GDPR), attracting the highest level of data protection. Where AI systems process this data, including through transcription of consultations, the lawful basis for processing, data retention policies, and rights of access and erasure must be clearly established. The European Commission's official guidance notes that the European Health Data Space Regulation, which entered into force in 2025 but whose provisions will apply progressively over subsequent years, provides an additional governance layer for clinical AI data use.

• Informed consent: In psychiatry, where patients may have conditions affecting their capacity to consent, the process for obtaining meaningful informed consent to AI involvement in care requires careful consideration. A 2025 governance protocol for AI-enabled psychotherapy proposed layered consent processes as a practical mechanism for addressing this challenge, explicitly aligned with EU AI Act and GDPR requirements.

What to ask a vendor before deploying an AI tool in a psychiatric practice

Psychiatrists and practice managers are, under the Act, classified as deployers of AI systems. This creates direct legal obligations, but it also positions them as informed procurers who should hold vendors to account. The following questions represent a minimum due diligence standard:

• Is this system classified as high-risk under the EU AI Act? If not, what documented assessment supports that conclusion?

• Does the system qualify as a medical device under the MDR? If so, does it hold CE marking, and which Notified Body conducted the conformity assessment?

• Has the system been clinically validated in a mental health population? Can validation data be shared, including performance metrics disaggregated by patient subgroup?

• Where is patient data processed and stored? Does the vendor confirm EU data residency, and what are the data retention and deletion policies?

• What audit trail does the system generate, and how can logs be accessed for clinical governance or legal review purposes?

• What human override mechanisms are built into the system, and how are they documented?

• How does the vendor handle model updates? Are updated versions subject to re-validation before deployment?

• What is the vendor's process for reporting and responding to incidents involving AI-generated outputs that may have contributed to patient harm?

The systematic review on mental health AI chatbots found that most systems rely on general-purpose LLMs and are deployed via consumer-facing platforms without clinical supervision, a pattern that is incompatible with the AI Act's requirements for high-risk systems in psychiatric settings.

How the AI Act interacts with existing medical device and data protection law

The AI Act is a horizontal regulation. It applies across sectors and sits alongside, rather than replacing, existing sector-specific legislation. For psychiatrists, this means that compliance with the AI Act does not discharge obligations under the MDR or GDPR, and vice versa.

The academic analysis of the AI Act in healthcare describes the Act as a "pioneering horizontal regulatory framework" and explicitly addresses the interaction between AI Act conformity obligations and MDR requirements. An AI tool used in psychiatric practice may simultaneously be subject to:

• EU AI Act high-risk obligations (if it meets the Annex III criteria)

• MDR obligations (if it qualifies as Software as a Medical Device)

• GDPR obligations (given that mental health data is a special category)

• National mental health data legislation in some EU member states, which may impose additional restrictions on the processing of psychiatric records

The Healthy Europe policy analysis notes that the European mental health app market contains thousands of products with limited clinical evaluation, and that dual compliance under the AI Act and MDR adds complexity that many vendors have not yet fully addressed. Psychiatrists should not assume that a product's presence on the market indicates full regulatory compliance, particularly during the current transition period.

There is also a recognised limitation in the current regulatory landscape. A peer-reviewed legal analysis has argued that the EU AI Act, while directly applicable to mental health AI, is insufficient on its own to address all the legal and ethical gaps in this domain. The Act does not resolve questions of clinical liability when AI contributes to a harmful decision, and national medical liability frameworks will continue to govern those questions independently.

Key dates and transition timelines psychiatrists should know

The AI Act is being implemented in phases, and not all obligations are yet in force. For psychiatrists evaluating tools now, the following timeline is directly relevant:

• February 2025: Provisions on prohibited AI practices entered into force. AI systems that exploit psychological vulnerabilities or use subliminal manipulation in clinical contexts were prohibited from this date.

• August 2025: Obligations relating to general-purpose AI models, including LLMs used as the foundation of clinical AI tools, entered into force.

• August 2026: The full high-risk compliance framework, including all conformity assessment, documentation, oversight, and transparency obligations, applies to AI systems in healthcare. This is the deadline by which providers and deployers of high-risk AI systems must be in full compliance.

• August 2027: An extended transition applies specifically to AI systems that are also regulated medical devices under the MDR or the In Vitro Diagnostic Medical Devices Regulation (IVDR), reflecting the longer conformity assessment timelines in the medical device sector.

The August 2026 deadline is the most immediately relevant for psychiatrists evaluating or deploying AI tools today. Tools being procured now will need to meet full high-risk compliance requirements within months of this article's publication. Psychiatrists and practice managers who are mid-procurement or mid-deployment should treat the compliance deadline as a live operational concern, not a future consideration.

A 50-state US legislative review published in JMIR Mental Health, while focused on the American context, identified a consistent pattern of clinicians and professional organisations remaining absent from AI policymaking, resulting in frameworks that diverge from clinical realities. The same risk exists in Europe. Psychiatrists who engage actively with the AI Act's requirements, as procurers, as deployers, and as contributors to professional guidance, are better placed to shape how these tools are implemented in practice than those who treat regulation as an external constraint.

Frequently asked questions

▶ Why do AI tools used in mental health settings face stricter regulation under the EU AI Act?

The EU AI Act's risk classification framework takes into account the vulnerability of the patient population, the severity of potential harms from incorrect AI outputs, and the complexity of clinical judgement in psychiatry. Mental health patients, including those in acute crisis or with conditions affecting decision-making capacity, are recognised under EU law as a vulnerable group. That recognition directly raises the regulatory weight applied to AI tools operating in psychiatric settings, even when those tools perform functions that would attract lighter requirements in other specialties.

▶ Which AI tools used in psychiatric practice are most likely to be classified as high-risk?

Several categories consistently attract high-risk classification under the Act. Risk stratification and triage tools, including those that assess suicide risk or predict psychiatric deterioration, fall clearly within this group. Diagnostic support tools that suggest diagnoses or diagnostic codes for mental health conditions are explicitly covered by Annex III of the Act. Clinical decision support tools that influence treatment decisions, AI-enabled psychotherapy agents, and mood or symptom tracking systems whose outputs directly inform clinical decisions are also likely to be classified as high-risk.

▶ Are clinical documentation tools, such as ambient scribes, automatically classified as high-risk in mental health settings?

Not automatically, but the threshold is lower in psychiatry than in other specialties. A tool that passively transcribes speech for a clinician to review sits at a different point on the risk spectrum than one that generates structured clinical notes or applies diagnostic codes. In psychiatry, clinical notes frequently inform decisions about compulsory treatment, capacity assessments, and safeguarding referrals. Where AI-generated notes feed directly into those decisions, even with nominal clinician review, the tool's output is functionally influencing a high-stakes decision affecting a vulnerable individual. If the tool also qualifies as Software as a Medical Device under the Medical Device Regulation, high-risk classification under the AI Act becomes more likely.

▶ What conformity requirements must a high-risk AI tool meet before it can be deployed in a psychiatric practice?

High-risk AI systems must satisfy several requirements before deployment. Vendors must maintain comprehensive technical documentation covering the system's design, training data, and performance validation. A documented risk management process is required. The system must include human oversight mechanisms that allow clinicians to override or disregard its outputs. Automatic logging of system operations must be in place to support post-hoc review. Where the tool also qualifies as a medical device, CE marking under the Medical Device Regulation is required alongside AI Act conformity. Vendors must also demonstrate defined levels of accuracy, robustness, and cybersecurity resilience.

▶ What transparency obligations apply when using AI in mental health consultations?

Patients must be informed when an AI system is used in a way that materially affects their care, even when the clinician retains final decision-making authority. Mental health data is classified as a special category under the General Data Protection Regulation, which means the lawful basis for processing, data retention policies, and patients' rights of access and erasure must be clearly established. In psychiatry, where patients may have conditions affecting their capacity to consent, obtaining meaningful informed consent to AI involvement in care requires particular care. A 2025 governance protocol proposed layered consent processes as a practical approach to this challenge.

▶ Can an AI tool that is prohibited under the EU AI Act be used in a mental health setting if it is clinically beneficial?

No. Prohibited AI practices are banned outright and cannot be deployed regardless of perceived clinical benefit. The Act identifies systems that exploit psychological vulnerabilities to manipulate behaviour in harmful ways as prohibited. Mental health chatbots that use persuasive dialogue or gamification to influence patient behaviour may cross into prohibited territory depending on their design and deployment context. The distinction between a prohibited system and a high-risk one is significant: high-risk systems can be deployed, but only after satisfying rigorous conformity requirements.

▶ What questions should a psychiatrist or practice manager ask a vendor before procuring an AI tool?

At a minimum, you should ask whether the system is classified as high-risk under the EU AI Act and, if not, what documented assessment supports that conclusion. Ask whether it qualifies as a medical device and, if so, whether it holds CE marking. Request clinical validation data specific to a mental health population, including performance metrics disaggregated by patient subgroup. Confirm where patient data is processed and stored, and whether EU data residency applies. Ask what audit trail the system generates, what human override mechanisms exist, how model updates are handled, and what the vendor's process is for reporting incidents involving AI-generated outputs that may have contributed to patient harm.

▶ How does the EU AI Act interact with the Medical Device Regulation and GDPR in psychiatric practice?

The EU AI Act sits alongside existing legislation rather than replacing it. An AI tool used in psychiatric practice may simultaneously be subject to EU AI Act high-risk obligations, Medical Device Regulation obligations if it qualifies as Software as a Medical Device, and General Data Protection Regulation obligations given that mental health data is a special category. Some EU member states also impose additional national restrictions on the processing of psychiatric records. Compliance with one framework does not discharge obligations under the others. A peer-reviewed legal analysis has noted that the AI Act alone is insufficient to address all legal and ethical gaps specific to mental health AI.

▶ What are the key EU AI Act compliance deadlines that psychiatrists should be aware of?

Provisions on prohibited AI practices entered into force in February 2025. Obligations relating to general-purpose AI models, including large language models used as the foundation of clinical AI tools, entered into force in August 2025. The full high-risk compliance framework, covering conformity assessment, documentation, oversight, and transparency obligations, applies from August 2026. An extended transition until August 2027 applies specifically to AI systems that are also regulated medical devices under the Medical Device Regulation or the In Vitro Diagnostic Medical Devices Regulation. Tools being procured now will need to meet full high-risk compliance requirements by August 2026.

▶ Does the EU AI Act resolve questions of clinical liability when AI contributes to a harmful decision in psychiatry?

No. A peer-reviewed legal analysis has confirmed that the EU AI Act does not resolve questions of clinical liability when AI contributes to a harmful decision. National medical liability frameworks continue to govern those questions independently. The Act establishes compliance and conformity obligations for providers and deployers, but it does not create a unified liability regime for AI-related clinical harm. Psychiatrists should seek legal advice specific to their jurisdiction when assessing liability exposure from AI tool deployment.